CEVEC Grants Full Distribution Rights for CAP®-CDM Cell Culture Medium and CAP®-CDM Feed to Xell
- CAP®-CDM Medium and Feed was developed by Xell for high performance cell cultures of the CAP®Go cell lines commercialized by CEVEC
- While in the past CAP®-CDM was sold exclusively by CEVEC to its customers, Xell will be the future sole distributor of the product
Cologne, Germany, January 25, 2019
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors today announced that it has granted full distribution rights for CAP®-CDM Medium and CAP®-CDM Feed to Xell AG.
CAP®-CDM Medium and Feed were developed by Xell on behalf of CEVEC for culturing CEVEC’s proprietary CAP®Go cell lines. Going forward Xell will be the sole distributor of the product and exclusively sell CAP®-CDM Medium and Feed to customers from academia as well as the biotechnology and pharmaceutical industry. CEVEC will receive royalties on future net sales. Further financial details were not disclosed.
CAP®-CDM Medium is a serum- and animal component-free, chemically defined cell culture medium. The product is available as liquid formulation and specifically optimized for CEVEC’S CAP®Go-based fermentation processes. It is suited for batch and fed batch processes, and gives optimal protein yields in fed batch cultures in combination with CAP®-CDM Feed supplement.
“As a leading company for state-of-the art cell culture media and feeds, Xell provides solutions that meet the individual needs of specific mammalian expression platforms and cell lines in order to facilitate highest product yields”, said Dr. Frederik Walter, Business Developer at Xell AG. “The cell culture medium we developed for CEVEC in combination with the complementing feed component is specially tailored to CEVEC’s CAP® cell lines and therefore enables high efficiency when growing CAP®Go suspension cells.”
“We are pleased that an experienced company like Xell will now do production and distribution of CAP®-CDM Medium and Feed out of one hand to our customers and partners” Dr. Nadine Sandhöfer, Director QA & Regulatory Affairs at CEVEC Pharmaceuticals GmbH commented. “Our CAP®Go technology for the production of difficult-to-express recombinant proteins with tailor-made glycosylation patterns brings completely unique features to biopharmaceuticals in terms of enhanced efficacy, stability and serum half-life as well as cost-efficient large-scale production.“
The CAP®Go technology for the fully scalable production of glycosylated recombinant proteins is based on the company’s proprietary CAP® cell line and comprises a comprehensive portfolio of glyco-optimized human suspension cell lines. CAP®Go cell lines differ in their glycosylation capabilities and enable the production of a variety of proteins with complex glycosylation structures such as plasma proteins, coagulation factors, high molecular mass multimeric proteins, and cytokines.
Validated by numerous partnerships in academia and industry, CAP®Go today is a leading expression system for difficult-to-express recombinant therapeutic proteins with tailor-made glycosylation patterns for significantly improved physicochemical and pharmacological properties.
About Xell AG:
Xell AG is a globally active biotech company with a strong focus on cell culture media as well as associated analytical and process services. Within ten successful years in the market, Xell has established itself as an experienced, reliable partner for the biopharmaceutical industry providing efficient off-the-shelf media and feed products, customized developments, as well as solid analyses.
About CEVEC:
CEVEC is a leading mammalian cell line developer and a center of expertise for the production of biopharmaceuticals and gene therapy vectors.
CAP®Go enables the production of proteins previously out of reach representing a significant proportion of the human proteome that is notoriously difficult to express in conventional cell lines such as CHO cells. The CAP®Go expression platform comprises a portfolio of glycosylation-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand, tailor-made glycosylation patterns.
CAP®GT is a fully scalable manufacturing platform for viral vector production. CEVEC has successfully developed CAP®GT suspension cell-derived viral packaging cell lines, including a stable, helper virus-free AAV production platform, which enable better scale-up and competitive production costs when compared to adherent cell culture systems. CAP®GT suspension cell lines grow to high cell densities and show excellent productivity for a broad range of viruses. Gene therapy vectors such as lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV) can be produced at industrial scale.
Follow CEVEC on LinkedIn.
Contact:
CEVEC Pharmaceuticals GmbH
Dr. Ulrich Kettling
VP Business Development
T.: +49 221 460 208 00
E.: bizdev@cevec.com
MC Services AG
Dr. Solveigh Mähler
Public Relations
T.: +49 211 529 252 19
E.: solveigh.maehler@mc-services.eu